RICHARD D. MEYER, M.D.; ROBERT P. LEWIS, M.D.; E. DUANE CARMALT, M.D.; SYDNEY M. FINEGOLD, M.D., F.A.C.P.
Amikacin is a new aminoglycoside antibiotic pharmacologically similar to kanamycin. It has a wide range of activity against Gram-negative bacilli, including many resistant to gentamicin. Thirty-six serious Gram-negative bacillary infections were treated with amikacin. Twenty-nine patients (80.6%) responded (cured or improved). Twelve of 13 patients with gentamicin-resistant pathogens responded. Minor ototoxicity occurred in 6 patients and was associated with prolonged therapy or previous aminoglycoside therapy. Possible nephrotoxicity with amikacin was found in 6 patients. Amikacin should be used primarily to treat suspected or known gentamicin-resistant pathogens.
MEYER RD, LEWIS RP, CARMALT ED, FINEGOLD SM. Amikacin Therapy for Serious Gram-Negative Bacillary Infections. Ann Intern Med. ;83:790–800. doi: 10.7326/0003-4819-83-6-790
Download citation file:
Published: Ann Intern Med. 1975;83(6):790-800.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use